1. Home
  2. HHH vs IMVT Comparison

HHH vs IMVT Comparison

Compare HHH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Howard Hughes Holdings Inc.

HHH

Howard Hughes Holdings Inc.

HOLD

Current Price

$82.67

Market Cap

5.0B

Sector

Real Estate

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.12

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHH
IMVT
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HHH
IMVT
Price
$82.67
$26.12
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$90.00
$29.13
AVG Volume (30 Days)
396.4K
1.6M
Earning Date
02-19-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
234.52
N/A
EPS
5.10
N/A
Revenue
$1,834,033,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.38
N/A
P/E Ratio
$16.07
N/A
Revenue Growth
69.81
N/A
52 Week Low
$61.41
$12.72
52 Week High
$91.07
$27.80

Technical Indicators

Market Signals
Indicator
HHH
IMVT
Relative Strength Index (RSI) 52.97 53.63
Support Level $80.95 $25.43
Resistance Level $83.65 $27.37
Average True Range (ATR) 1.63 1.19
MACD 0.37 -0.11
Stochastic Oscillator 84.10 47.74

Price Performance

Historical Comparison
HHH
IMVT

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: